Promising antibody therapy aims to keep kidney disease in remission
NCT ID NCT07233330
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests a drug called obinutuzumab in 10 adults with a kidney condition called nephrotic syndrome that keeps coming back despite standard treatments. The goal is to see if a single course can prevent relapses for at least 12 months and reduce the need for repeated rituximab therapy. Participants will receive obinutuzumab infusions and be monitored for safety and how long their B cells stay depleted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME，IDIOPATHIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
Ranica, BG, 24020, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.